Minnesota Oncology Hematology PA-Maplewood
Welcome,         Profile    Billing    Logout  
 1092 Trials 
447 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Benson, Al B
BTCRC-GI15-015, NCT03283761: FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma

Completed
2
39
US
Nab-paclitaxel 150 mg/m^2, Abraxane®, Oxaliplatin 85 mg/m^2, Eloxatin, 5-FU 1200 mg/m^2 x 2 D, Adrucil, Fluorouracil, Leucovorin 400 mg/m^2
Al B. Benson, III, MD, Celgene Corporation, Big Ten Cancer Research Consortium
Gastro-Esophageal Junction Adenocarcinoma, Gastric Cancer
12/22
01/23
NCT03861702: Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma:

Active, not recruiting
2
28
US
FOLFOX regimen, Liposomal Irinotecan, nal-Irinotecan
Nelson Yee, Ipsen
Locally Advanced Pancreatic Carcinoma(LAPC)
08/23
08/24
NCT04505839: First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors

Completed
1
32
US
STP1002, Basroparib
ST Pharm Co., Ltd., KCRN Research, LLC
Advanced Solid Tumor
03/23
03/23
Walsh, William
JADE, NCT06256588: A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

Recruiting
3
864
Europe, Canada, Japan, US, RoW
Dostarlimab, Placebo
GlaxoSmithKline
Neoplasms, Head and Neck
05/28
07/29
NCT03994627: Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma

Available
N/A
Europe, Canada, US, RoW
Olaratumab, LY3012207
Eli Lilly and Company
Soft Tissue Sarcoma
 
 
Lerner, Seth P
NCT05710848: A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer

Recruiting
1/2
75
US
STM-416
SURGE Therapeutics
Non-muscle-invasive Bladder Cancer
06/24
09/24
Hesketh, Paul J
ASTRIDE, NCT05468489: To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

Recruiting
3
200
US
Serplulimab + chemotherapy (carboplatin-etoposide), Atezolizumab + chemotherapy (carboplatin-etoposide)
Shanghai Henlius Biotech
Extensive Stage Small Cell Lung Cancer
10/24
12/25
SWOG S2302, NCT05633602: Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Recruiting
3
700
US
Chemotherapy, Chemo, Chemotherapy (NOS), Chemotherapy, Cancer, General, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Ramucirumab, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, LY3009806
SWOG Cancer Research Network, National Cancer Institute (NCI), Eli Lilly and Company, Merck Sharp & Dohme LLC
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
03/25
03/28
Carlson, Jay W
SWOG S2302, NCT05633602: Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Recruiting
3
700
US
Chemotherapy, Chemo, Chemotherapy (NOS), Chemotherapy, Cancer, General, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Ramucirumab, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, LY3009806
SWOG Cancer Research Network, National Cancer Institute (NCI), Eli Lilly and Company, Merck Sharp & Dohme LLC
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
03/25
03/28
PACES, NCT01349881: S0820, Adenoma and Second Primary Prevention Trial

Active, not recruiting
3
354
US
Eflornithine placebo & sulindac placebo, eflornithine & sulindac placebo, Eflornithine placebo & sulindac, Eflornithine plus sulindac
SWOG Cancer Research Network, National Cancer Institute (NCI), Cancer Prevention Pharmaceuticals, Inc.
Colorectal Neoplasms
02/27
02/32
A011801, NCT04457596: T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Calendar Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer
Recruiting
3
1031
Canada, US
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.
Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Synchronous Bilateral Breast Carcinoma
01/28
05/35
DRAMMATIC, NCT04071457: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Hourglass Jan 2023 - Jun 2023 : From trial for patients with r/r multiple myeloma treated with an IMiD and PI
Recruiting
3
1100
Canada, US
Lenalidomide, CC-5013, Revlimid, Daratumumab/rHuPH20
SWOG Cancer Research Network, National Cancer Institute (NCI), Janssen, LP
Multiple Myeloma
07/29
07/40
CIRCULATE-US, NCT05174169: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Recruiting
2/3
1912
Canada, US
Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month
NRG Oncology, Natera, Inc., National Cancer Institute (NCI)
Stage III Colon Cancer
03/29
03/30
A071401, NCT02523014: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Recruiting
2
124
US
Vismodegib, GDC-0449, FAK Inhibitor GSK2256098, Capivasertib, AZD5363, Abemaciclib
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), GlaxoSmithKline, Genentech, Inc., Brain Science Foundation
Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
10/24
10/24
PRECISION 1, NCT05103358: Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes

Active, not recruiting
2
120
US, RoW
nab-sirolimus, ABI-009
Aadi Bioscience, Inc.
Tumor, Tumor, Solid, Metastasis, Metastatic Cancer, Cancer, Cancer Metastatic, Tumors, Neoplasms, Neoplasm Metastasis, Solid Tumor, Advanced Solid Tumor, Advanced Cancer, Malignant Solid Tumor, Malignant Solid Neoplasm, Malignant Neoplasm, Malignant Tumor, TSC, TSC1, TSC2, Metastatic Solid Tumor, Metastatic Neoplasm
12/24
12/25
NCT04647916: Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases

Recruiting
2
44
US
Sacituzumab Govitecan, hRS7-SN38 Antibody Drug Conjugate, IMMU-132, RS7-SN38, Sacituzumab Govitecan-hziy, Trodelvy
SWOG Cancer Research Network, National Cancer Institute (NCI), Gilead Sciences
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic HER2 Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8
02/25
12/26
Mulcahy, Mary
CIRCULATE-US, NCT05174169: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Recruiting
2/3
1912
Canada, US
Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month
NRG Oncology, Natera, Inc., National Cancer Institute (NCI)
Stage III Colon Cancer
03/29
03/30
SGNLVA-005, NCT04032704 / 2019-001946-17: A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Terminated
2
205
Europe, US, RoW
ladiratuzumab vedotin, SGN-LIV1A, pembrolizumab, Keytruda
Seagen Inc., Merck Sharp & Dohme LLC
Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Prostate Cancer, Melanoma
11/23
11/23
Deming, Richard L
SWOG S2302, NCT05633602: Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Recruiting
3
700
US
Chemotherapy, Chemo, Chemotherapy (NOS), Chemotherapy, Cancer, General, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Ramucirumab, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, LY3009806
SWOG Cancer Research Network, National Cancer Institute (NCI), Eli Lilly and Company, Merck Sharp & Dohme LLC
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
03/25
03/28
PACES, NCT01349881: S0820, Adenoma and Second Primary Prevention Trial

Active, not recruiting
3
354
US
Eflornithine placebo & sulindac placebo, eflornithine & sulindac placebo, Eflornithine placebo & sulindac, Eflornithine plus sulindac
SWOG Cancer Research Network, National Cancer Institute (NCI), Cancer Prevention Pharmaceuticals, Inc.
Colorectal Neoplasms
02/27
02/32
A011801, NCT04457596: T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Calendar Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer
Recruiting
3
1031
Canada, US
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.
Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Synchronous Bilateral Breast Carcinoma
01/28
05/35
DRAMMATIC, NCT04071457: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Hourglass Jan 2023 - Jun 2023 : From trial for patients with r/r multiple myeloma treated with an IMiD and PI
Recruiting
3
1100
Canada, US
Lenalidomide, CC-5013, Revlimid, Daratumumab/rHuPH20
SWOG Cancer Research Network, National Cancer Institute (NCI), Janssen, LP
Multiple Myeloma
07/29
07/40
CIRCULATE-US, NCT05174169: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Recruiting
2/3
1912
Canada, US
Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month
NRG Oncology, Natera, Inc., National Cancer Institute (NCI)
Stage III Colon Cancer
03/29
03/30
A071401, NCT02523014: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Recruiting
2
124
US
Vismodegib, GDC-0449, FAK Inhibitor GSK2256098, Capivasertib, AZD5363, Abemaciclib
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), GlaxoSmithKline, Genentech, Inc., Brain Science Foundation
Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
10/24
10/24
NCT03994796: Genetic Testing in Guiding Treatment for Patients With Brain Metastases

Recruiting
2
186
US
Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib, Adagrasib, MRTX849
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Mirati Therapeutics Inc., Genentech, Inc., Eli Lilly and Company, Kazia Therapeutics Limited
CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation, PI3K Gene Mutation, ROS1 Gene Mutation, KRAS G12C Mutation
10/24
06/25
NCT04647916: Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases

Recruiting
2
44
US
Sacituzumab Govitecan, hRS7-SN38 Antibody Drug Conjugate, IMMU-132, RS7-SN38, Sacituzumab Govitecan-hziy, Trodelvy
SWOG Cancer Research Network, National Cancer Institute (NCI), Gilead Sciences
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic HER2 Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8
02/25
12/26
Dakhil, Shaker
JADE, NCT06256588: A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

Recruiting
3
864
Europe, Canada, Japan, US, RoW
Dostarlimab, Placebo
GlaxoSmithKline
Neoplasms, Head and Neck
05/28
07/29
ASTRIDE, NCT05468489: To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

Recruiting
3
200
US
Serplulimab + chemotherapy (carboplatin-etoposide), Atezolizumab + chemotherapy (carboplatin-etoposide)
Shanghai Henlius Biotech
Extensive Stage Small Cell Lung Cancer
10/24
12/25
Be6A Lung-01, NCT06012435: A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

Recruiting
3
600
Europe, Canada, Japan, US, RoW
sigvotatug vedotin, SGN-B6A, docetaxel
Seagen Inc.
Carcinoma, Non-Small-Cell Lung
07/26
07/28
A011801, NCT04457596: T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Calendar Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer
Recruiting
3
1031
Canada, US
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.
Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Synchronous Bilateral Breast Carcinoma
01/28
05/35
CIRCULATE-US, NCT05174169: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Recruiting
2/3
1912
Canada, US
Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month
NRG Oncology, Natera, Inc., National Cancer Institute (NCI)
Stage III Colon Cancer
03/29
03/30
TRIO-US L-07, NCT03672773: Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer

Recruiting
2
28
US
Talazoparib, BMN 673, BMN-673, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac
Jonsson Comprehensive Cancer Center, Translational Research in Oncology, Pfizer
Recurrent Extensive Stage Small Cell Lung Carcinoma, Refractory Extensive Stage Small Cell Lung Carcinoma
10/24
10/25
MIT-001, NCT04651634: for Prevention of CCRT-Induced OM in HNSCC Patients

Recruiting
2
60
US, RoW
MIT-001 plus CCRT
MitoImmune Therapeutics
Head and Neck Squamous Cell Carcinoma, Oral Mucositis
04/24
12/24
ASC2ESCALATE, NCT05384587: Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia

Recruiting
2
182
US
asciminib, ABL001
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia - Chronic Phase
02/26
02/27
TRIO-US B-12 TALENT, NCT04553770: Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

Checkmark Presentation of data from TALENT trial for HER2 Low, HR+ breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Presentation of data from TALENT trial for HER2 Low, HR+ breast cancer at SABCS 2022
Recruiting
2
88
US
Anastrozole, Anastrazole, Arimidex, ICI D1033, ICI-D1033, ZD-1033, Therapeutic Conventional Surgery, Trastuzumab Deruxtecan, DS-8201, DS-8201a, Enhertu, Fam-trastuzumab Deruxtecan-nxki, WHO 10516
Jonsson Comprehensive Cancer Center, Translational Research in Oncology-U.S, Daiichi Sankyo Co., Ltd.
Early-stage Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer
09/25
09/25
BRI-ROL-001, NCT03328026: Combination Study of SV-BR-1-GM With Retifanlimab

Checkmark In combination with Bria-IMT for advanced breast cancer
Sep 2019 - Sep 2019: In combination with Bria-IMT for advanced breast cancer
Checkmark Safety data in combination with Bria-IMT
Dec 2018 - Dec 2018: Safety data in combination with Bria-IMT
Checkmark Anticipated efficiency data in combination with Bria-IMT
More
Enrolling by invitation
1/2
36
US
SV-BR-1-GM, Low dose cyclophosphamide, Cytoxan, Interferon Inoculation, retifanlimab, INCMGA00012
BriaCell Therapeutics Corporation, LumaBridge
Breast Cancer, Breast Neoplasm, Metastatic Breast Cancer, Breast Cancer Metastatic
06/24
06/24
iinnovate-2, NCT05556616: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma

Active, not recruiting
1
120
Europe, US, RoW
Modakafusp alfa, TAK-573, Lenalidomide, Bortezomib, Carfilzomib, Daratumumab, Pomalidomide
Takeda
Multiple Myeloma
01/24
06/24
DREAMM 13, NCT04398680: A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function

Recruiting
1
28
Europe, US, RoW
Belantamab mafodotin
GlaxoSmithKline
Multiple Myeloma
11/25
11/25
Sperduto, Paul
METIS, NCT02831959: Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).

Active, not recruiting
3
270
Europe, Canada, US, RoW
NovoTTF-200M device, Best Standard of Care
NovoCure GmbH
Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
12/24
12/24
Huang, Chao H
NCT05353257 / 2022-002226-27: A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

Recruiting
3
482
Europe, US, RoW
HLX10, Serplulimab, carboplatin/cisplatin-etoposide, Thoracic radiotherapy, Placebo, Prophylactic Cranial Irradiation (PCI)
Shanghai Henlius Biotech, Shanghai Henlius Biotech, Inc.
Limited-Stage Small Cell Lung Cancer
12/24
06/26
SWOG S2302, NCT05633602: Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Recruiting
3
700
US
Chemotherapy, Chemo, Chemotherapy (NOS), Chemotherapy, Cancer, General, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Ramucirumab, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, LY3009806
SWOG Cancer Research Network, National Cancer Institute (NCI), Eli Lilly and Company, Merck Sharp & Dohme LLC
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
03/25
03/28
CARMEN-LC05, NCT04524689 / 2020-000035-50: Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC

Hourglass Apr 2022 - Dec 2022 : Data from CARMEN-LC05 trial in combination with pembrolizumab for PDL1+ advanced NSCLC
Active, not recruiting
2
57
Europe, US, RoW
SAR408701 (Tusamitamab ravtansine), Tusamitamab ravtansine, Pembrolizumab, Keytruda, Cisplatin, Carboplatin, Pemetrexed
Sanofi
Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
03/24
12/24
Wender, Donald B
INTEGRATEIIb, NCT04879368 / 2020-004617-12: RegoNivo vs Standard of Care Chemotherapy in AGOC

Active, not recruiting
3
450
Europe, Japan, US, RoW
Regorafenib, Stivarga, Nivolumab, Opdivo, Docetaxel, Taxotere, Paclitaxel, Abraxane, Irinotecan, Camptosar, Trifluridine/Tipracil, Lonsurf
Australasian Gastro-Intestinal Trials Group, Bayer, Bristol-Myers Squibb, University of Sydney, Academic and Community Cancer Research United, Taiwanese Cooperative Oncology Group, Frankfurter Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, National Cancer Center Hospital East, Syneos Health
Gastro-Oesophageal Cancer
06/25
06/26
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

Jan 2023 - Dec 2023: DOR/PFS data from P1b portion of P1b/3 SYMPHONY-1 trial in combination with Revlimid and Rituxan for relapsed/refractory follicular lymphoma
Hourglass Jan 2023 - Dec 2023 : First interim futility data from P3 portion of P1b/3 SYMPHONY-1 trial in combination with Rituxan for relapsed/refractory follicular lymphoma
Hourglass Jan 2022 - Dec 2022 : Completion of enrollment of P3 portion of P1b/3 trial for r/r follicular lymphoma
Checkmark Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
Jun 2022 - Jun 2022: Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
More
Recruiting
3
612
Europe, Canada, US, RoW
Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab
Epizyme, Inc.
Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
03/26
03/29
NCT05028348 / 2021-001691-41: A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

Calendar Jul 2024 - Dec 2024: Top-line data from XPORT-MM-031 trial in combination with pomalidomide and dexamethasone for multiple myeloma
Jun 2023 - Dec 2023: Completion of enrolment of trial in combination with pomalidomide and dexamethasone for multiple myeloma
Recruiting
3
222
Europe, US
Selinexor, KPT-330, Elotuzumab, Pomalidomide, Dexamethasone Oral
Stichting European Myeloma Network, Karyopharm Therapeutics Inc
Multiple Myeloma
03/26
03/29
KEYNOTE-D74, NCT05911295: Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

Recruiting
3
700
Canada, US, RoW
disitamab vedotin, RC48, RC48-ADC, pembrolizumab, KEYTRUDA®, gemcitabine, Gemzar, cisplatin, carboplatin
Seagen Inc., RemeGen Co., Ltd., Merck Sharp & Dohme LLC
Urothelial Carcinoma
06/26
04/29
PACES, NCT01349881: S0820, Adenoma and Second Primary Prevention Trial

Active, not recruiting
3
354
US
Eflornithine placebo & sulindac placebo, eflornithine & sulindac placebo, Eflornithine placebo & sulindac, Eflornithine plus sulindac
SWOG Cancer Research Network, National Cancer Institute (NCI), Cancer Prevention Pharmaceuticals, Inc.
Colorectal Neoplasms
02/27
02/32
A011801, NCT04457596: T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Calendar Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer
Recruiting
3
1031
Canada, US
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.
Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Synchronous Bilateral Breast Carcinoma
01/28
05/35
CIRCULATE-US, NCT05174169: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Recruiting
2/3
1912
Canada, US
Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month
NRG Oncology, Natera, Inc., National Cancer Institute (NCI)
Stage III Colon Cancer
03/29
03/30
iinnovate-1, NCT03215030: A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

Active, not recruiting
1/2
336
Europe, Canada, Japan, US, RoW
Modakafusp alfa, TAK-573, TEV-48573, Dexamethasone
Takeda
Multiple Myeloma
02/24
09/24
Stella, Philip J
CHIO3, NCT04062708: Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer

Active, not recruiting
2
38
US
Durvalumab, Imfinzi, Surgery, Radiotherapy
Alliance Foundation Trials, LLC., AstraZeneca
Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
12/25
06/26
A071401, NCT02523014: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Recruiting
2
124
US
Vismodegib, GDC-0449, FAK Inhibitor GSK2256098, Capivasertib, AZD5363, Abemaciclib
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), GlaxoSmithKline, Genentech, Inc., Brain Science Foundation
Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
10/24
10/24
TAPUR, NCT02693535: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Recruiting
2
3791
US
Palbociclib, Ibrance, Sunitinib, Sutent, Temsirolimus, Torisel, Trastuzumab and Pertuzumab, Herceptin and Perjeta, Vemurafenib and Cobimetinib, Zelboraf and Cotellic, Regorafenib, Stivarga, Olaparib, Lynparza, Pembrolizumab, Keytruda, Nivolumab and Ipilimumab, Opdivo and Yervoy, Abemaciclib, Verzenio, Talazoparib, Talzenna, Atezolizumab and PHESGO, Tecentriq and PHESGO, Atezolizumab and Talazoparib, Tecentriq and Talzenna, Entrectinib, Rozlytrek, Larotrectinib, Vitrakvi, Tucatinib plus Trastuzumab Subcutaneous (SC), Tukysa and Herceptin Hylecta, Futibatinib, Lytgobi
American Society of Clinical Oncology, AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc., Merck Sharp & Dohme LLC, Pfizer, Boehringer Ingelheim, Seagen Inc., Taiho Oncology, Inc.
Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
12/24
12/25
Reynolds, Christopher
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

Jan 2023 - Dec 2023: DOR/PFS data from P1b portion of P1b/3 SYMPHONY-1 trial in combination with Revlimid and Rituxan for relapsed/refractory follicular lymphoma
Hourglass Jan 2023 - Dec 2023 : First interim futility data from P3 portion of P1b/3 SYMPHONY-1 trial in combination with Rituxan for relapsed/refractory follicular lymphoma
Hourglass Jan 2022 - Dec 2022 : Completion of enrollment of P3 portion of P1b/3 trial for r/r follicular lymphoma
Checkmark Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
Jun 2022 - Jun 2022: Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
More
Recruiting
3
612
Europe, Canada, US, RoW
Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab
Epizyme, Inc.
Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
03/26
03/29
A011801, NCT04457596: T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Calendar Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer
Recruiting
3
1031
Canada, US
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.
Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Synchronous Bilateral Breast Carcinoma
01/28
05/35
Rowland, Kendrith M
PACES, NCT01349881: S0820, Adenoma and Second Primary Prevention Trial

Active, not recruiting
3
354
US
Eflornithine placebo & sulindac placebo, eflornithine & sulindac placebo, Eflornithine placebo & sulindac, Eflornithine plus sulindac
SWOG Cancer Research Network, National Cancer Institute (NCI), Cancer Prevention Pharmaceuticals, Inc.
Colorectal Neoplasms
02/27
02/32
BRI-ROL-001, NCT03328026: Combination Study of SV-BR-1-GM With Retifanlimab

Checkmark In combination with Bria-IMT for advanced breast cancer
Sep 2019 - Sep 2019: In combination with Bria-IMT for advanced breast cancer
Checkmark Safety data in combination with Bria-IMT
Dec 2018 - Dec 2018: Safety data in combination with Bria-IMT
Checkmark Anticipated efficiency data in combination with Bria-IMT
More
Enrolling by invitation
1/2
36
US
SV-BR-1-GM, Low dose cyclophosphamide, Cytoxan, Interferon Inoculation, retifanlimab, INCMGA00012
BriaCell Therapeutics Corporation, LumaBridge
Breast Cancer, Breast Neoplasm, Metastatic Breast Cancer, Breast Cancer Metastatic
06/24
06/24
NCT05548296: A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma

Recruiting
1/2
390
US
ACR-368, prexasertib, Gemcitabine, OncoSignature
Acrivon Therapeutics, GOG Foundation
Platinum-resistant Ovarian Cancer, Endometrial Adenocarcinoma, Urothelial Carcinoma
07/26
12/27
Acclaim-1, NCT04486833: Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib

Recruiting
1/2
158
US
quaratusugene ozeplasmid, Reqorsa, osimertinib, Tagrisso, Platinum-Based Chemotherapy, cisplatin, carboplatin
Genprex, Inc.
Carcinoma, Non-Small Cell Lung
12/26
12/27
Ali, Haythem
VOICE, NCT04648020: Clonidine HCl MBT vs. Placebo to Prevent Chemoradiotherapy-Induced Severe Oral Mucositis in Oropharyngeal Cancer.

Terminated
2b
190
Europe, US
Clonidine HCl Mucoadhesive Buccal Tablet, Validive®, Placebo Mucoadhesive Buccal Tablet
Monopar Therapeutics
Chemoradiotherapy-Induced Severe Oral Mucositis
05/23
05/23
NCT03994796: Genetic Testing in Guiding Treatment for Patients With Brain Metastases

Recruiting
2
186
US
Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib, Adagrasib, MRTX849
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Mirati Therapeutics Inc., Genentech, Inc., Eli Lilly and Company, Kazia Therapeutics Limited
CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation, PI3K Gene Mutation, ROS1 Gene Mutation, KRAS G12C Mutation
10/24
06/25
Leach, Joseph
NCT03854110: Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine

Recruiting
1
64
US
GP-2250, gemcitabine
Geistlich Pharma AG, Translational Drug Development
Pancreatic Cancer, Adult
09/24
12/24
Burton, Gary
ARTEST, NCT04869943 / 2021-002176-39: Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer

Terminated
3
52
Europe, US, RoW
Enobosarm, VERU-024, Exemestane, Mestane
Veru Inc.
Metastatic Breast Cancer
01/24
01/24
A011801, NCT04457596: T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Calendar Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer
Recruiting
3
1031
Canada, US
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.
Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Synchronous Bilateral Breast Carcinoma
01/28
05/35
NCT05079360: Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer

Withdrawn
2
200
US
Sabizabulin, Veru-111, Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator, exemestane
Veru Inc.
Metastatic Breast Cancer
03/24
05/24
NCT03994796: Genetic Testing in Guiding Treatment for Patients With Brain Metastases

Recruiting
2
186
US
Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib, Adagrasib, MRTX849
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Mirati Therapeutics Inc., Genentech, Inc., Eli Lilly and Company, Kazia Therapeutics Limited
CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation, PI3K Gene Mutation, ROS1 Gene Mutation, KRAS G12C Mutation
10/24
06/25
Merchant, Joseph
A011801, NCT04457596: T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Calendar Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer
Recruiting
3
1031
Canada, US
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.
Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Synchronous Bilateral Breast Carcinoma
01/28
05/35
CIRCULATE-US, NCT05174169: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Recruiting
2/3
1912
Canada, US
Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month
NRG Oncology, Natera, Inc., National Cancer Institute (NCI)
Stage III Colon Cancer
03/29
03/30
A071401, NCT02523014: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Recruiting
2
124
US
Vismodegib, GDC-0449, FAK Inhibitor GSK2256098, Capivasertib, AZD5363, Abemaciclib
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), GlaxoSmithKline, Genentech, Inc., Brain Science Foundation
Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
10/24
10/24
NCT03994796: Genetic Testing in Guiding Treatment for Patients With Brain Metastases

Recruiting
2
186
US
Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib, Adagrasib, MRTX849
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Mirati Therapeutics Inc., Genentech, Inc., Eli Lilly and Company, Kazia Therapeutics Limited
CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation, PI3K Gene Mutation, ROS1 Gene Mutation, KRAS G12C Mutation
10/24
06/25
realMIND, NCT04981795: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL

Recruiting
N/A
100
US
Tafasitamab
Incyte Corporation, Iqvia Pty Ltd
Diffuse Large B-cell Lymphoma
10/25
08/26
Ellerton, John
SWOG S2302, NCT05633602: Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Recruiting
3
700
US
Chemotherapy, Chemo, Chemotherapy (NOS), Chemotherapy, Cancer, General, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Ramucirumab, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, LY3009806
SWOG Cancer Research Network, National Cancer Institute (NCI), Eli Lilly and Company, Merck Sharp & Dohme LLC
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
03/25
03/28
PACES, NCT01349881: S0820, Adenoma and Second Primary Prevention Trial

Active, not recruiting
3
354
US
Eflornithine placebo & sulindac placebo, eflornithine & sulindac placebo, Eflornithine placebo & sulindac, Eflornithine plus sulindac
SWOG Cancer Research Network, National Cancer Institute (NCI), Cancer Prevention Pharmaceuticals, Inc.
Colorectal Neoplasms
02/27
02/32
A011801, NCT04457596: T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Calendar Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer
Recruiting
3
1031
Canada, US
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.
Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Synchronous Bilateral Breast Carcinoma
01/28
05/35
CIRCULATE-US, NCT05174169: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Recruiting
2/3
1912
Canada, US
Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month
NRG Oncology, Natera, Inc., National Cancer Institute (NCI)
Stage III Colon Cancer
03/29
03/30
KEYNOTE B36, NCT04892472: EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer

Recruiting
2
100
US
NovoTTF-200T, Pembrolizumab (MK-3475) 200 mg
NovoCure GmbH, Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
07/24
12/26
A071401, NCT02523014: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Recruiting
2
124
US
Vismodegib, GDC-0449, FAK Inhibitor GSK2256098, Capivasertib, AZD5363, Abemaciclib
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), GlaxoSmithKline, Genentech, Inc., Brain Science Foundation
Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
10/24
10/24
BA3011-002, NCT04681131: CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC

Recruiting
2
240
Europe, US, RoW
CAB-AXL-ADC, BA3011, PD-1 inhibitor
BioAtla, Inc.
Non-Small-Cell Lung Cancer
08/25
08/25
BA3021-001, NCT03504488: CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)

Recruiting
1/2
420
Europe, US, RoW
CAB-ROR2-ADC, BA3021, PD-1 inhibitor
BioAtla, Inc.
Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma, Head and Neck Cancer
12/25
12/25
O'Dea, Anne
A011801, NCT04457596: T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Calendar Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer
Recruiting
3
1031
Canada, US
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.
Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Synchronous Bilateral Breast Carcinoma
01/28
05/35
Patel, Sanjay
NCT04358809: Clinical Trial of Mycobacterium w in COVID-19 Positive Patients, Hospitalized But Not Critically Ill

Recruiting
3
480
RoW
Suspension of heat killed (autoclaved) Mycobacterium w, Placebo
Cadila Pharnmaceuticals, Council of Scientific and Industrial Research, India
COVID-19
02/21
04/21
NIMBLE, NCT04718389 / 2020-003612-28: A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

Hourglass Feb 2024 - Jun 2024 : Acceptance of regulatory submission in China for CRSwNP
Recruiting
3
1700
Europe, Canada, Japan, US, RoW
GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS)
GlaxoSmithKline, Iqvia Pty Ltd
Asthma
09/25
09/25
SUPRA, NCT04861038: Study Using Negative Pressure to Reduce Apnea

Active, not recruiting
N/A
900
US
aerSleep II
Sommetrics, Inc.
Sleep Apnea, Obstructive, Apnea, Sleep
12/25
12/25
Sukari, Ammar
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Recruiting
3
700
Europe, Canada, Japan, US, RoW
Xevinapant (Debio 1143), IMRT, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Head and Neck Cancer
10/27
12/30
KEYNOTE-E02, NCT03485209 / 2017-005076-26: Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

Recruiting
2
692
Europe, Canada, US
tisotumab vedotin, TIVDAK, pembrolizumab, KEYTRUDA®, carboplatin, cisplatin
Seagen Inc., Genmab, Merck Sharp & Dohme LLC
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
04/25
11/26
VERSATILE002, NCT04260126: Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC

Checkmark Data from VERSATILE-002 clinical trial in combination with PDS0101 for metastatic head and neck cancer at MHNCS 2022
Feb 2022 - Feb 2022: Data from VERSATILE-002 clinical trial in combination with PDS0101 for metastatic head and neck cancer at MHNCS 2022
Active, not recruiting
2
95
Europe, US
Pembrolizumab (KEYTRUDA®) and PDS0101
PDS Biotechnology Corp., Merck Sharp & Dohme LLC
Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Neoplasms, Head and Neck
06/25
06/25
SGNDV-005, NCT06003231: A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

Recruiting
2
160
Canada, US, RoW
disitamab vedotin, RC48, RC48-ADC
Seagen Inc.
Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms
05/26
05/28
Iintune-1, NCT04420884 / 2022-000528-39: A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Recruiting
1/2
368
Europe, Canada, Japan, US, RoW
Dazostinag, TAK-676, Pembrolizumab, Platinum, 5-fluorouracil
Takeda, Takeda Development Center Americas, Inc. (TDC Americas)
Solid Neoplasms
01/26
01/26
NCT05443126: A Study of EP0031 in Patients With Advanced RET-altered Malignancies

Recruiting
1/2
265
Europe, US
EP0031
Ellipses Pharma
Advanced Solid Tumor
12/26
06/27
Study 1100, NCT03589339: NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

Recruiting
1
145
US
NBTXR3, SABR, Stereotaxic Ablative Radiotherapy, Stereotaxic Body Radiation Therapy, Nivolumab, Opdivo, Pembrolizumab, Keytruda
Nanobiotix
Radiotherapy, Immunotherapy, Microsatellite Instability-High Solid Malignant Tumour, Metastasis From Malignant Tumor of Liver, Squamous Cell Carcinoma of Head and Neck, Metastasis From Malignant Tumor of Cervix, Metastatic Renal Cell Carcinoma, Metastasis From Malignant Melanoma of Skin (Disorder), Metastatic Triple-Negative Breast Carcinoma, Metastatic NSCLC, Metastasis From Malignant Tumor of Bladder (Disorder)
04/27
05/28
KEYNOTE-A78, NCT03978689: A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma

Active, not recruiting
1
85
US
CUE-101, KEYTRUDA®, Pembrolizumab
Cue Biopharma, Merck Sharp & Dohme LLC
Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Carcinoma
11/24
05/25
HyperlynX, NCT06056310: Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN

Recruiting
1
40
Europe, US, RoW
Xevinapant, Debio 1143, Cisplatin, intensity-modulated radiation therapy (IMRT)
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Head and Neck Cancer
04/25
04/25
SGNPDL1V-001, NCT05208762: A Study of SGN-PDL1V in Advanced Solid Tumors

Recruiting
1
322
Europe, Canada, US
SGN-PDL1V, pembrolizumab, Keytruda
Seagen Inc.
Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma, Ovarian Neoplasms, Melanoma, Triple Negative Breast Neoplasms, Gastric Cancer
07/25
12/26
NCT04797390: A Study Evaluating an Advanced Pneumatic Compression Device Versus Usual Care for Treatment of Head and Neck Lymphedema

Active, not recruiting
N/A
250
US
Advanced Pneumatic Compression Device (APCD), Flexitouch, Flexitouch Plus, Usual Care, Complete Decongestive Therapy (CDT), Manual Lymphatic Drainage (MLD)
Tactile Medical, Vanderbilt University Medical Center
Lymphedema, Lymphedema of Face, Lymphedema, Secondary, Lymphedema Due to Radiation, Lymphedema; Surgical
01/25
01/25
Forsyth, Peter
FiTNEss, NCT03720041 / 2018-003590-10: Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma

Recruiting
3
740
Europe
R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm, Ninlaro, Revlimid, R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - adaptive arm, R2: Lenalidomide plus placebo maintenance, R2: Lenalidomide + ixazomib maintenance
University of Leeds, Cancer Research UK, Takeda, Celgene
Multiple Myeloma
12/24
12/24
ACCoRd, NCT03562169: The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII

Recruiting
3
406
Europe
Ixazomib, thalidomide, & dexamethasone (ITD) re-induction, Conventional autologous stem cell transplant (ASCT-con), Augmented autologous stem cell transplant (ASCT-aug), ITD consolidation and ixazomib maintenance vs. No further therapy
University of Leeds, Cancer Research UK, Takeda
Multiple Myeloma
03/26
03/27
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
NCT02681549: Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer

Recruiting
2
53
US
Pembrolizumab plus Bevacizumab
Yale University, National Cancer Institute (NCI), Merck Sharp & Dohme LLC
Melanoma, Non-small Cell Lung Cancer, Brain Metastasis
04/25
07/25
NCT04588545: Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease

Recruiting
1/2
39
US
Radiation Therapy, Pertuzumab, Trastuzumab
H. Lee Moffitt Cancer Center and Research Institute, Genentech, Inc.
HER2-positive Breast Cancer, Leptomeningeal Metastasis, Leptomeningeal Disease
11/24
11/24
MCC-20899, NCT04923542: Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases

Recruiting
1/2
31
US
Stereotactic Radiosurgery (SRS), Abemaciclib, Verzenio, Ramiven, Endocrine therapy, hormone therapy
H. Lee Moffitt Cancer Center and Research Institute, Eli Lilly and Company
Brain Metastases, HR+ Metastatic Breast Cancer
12/24
12/24
 

Download Options